1.02
-0.12(-10.53%)
Currency In USD
| Previous Close | 1.14 |
| Open | 1.07 |
| Day High | 1.07 |
| Day Low | 1.01 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.81 |
| Volume | 626,100 |
| Average Volume | 3.95M |
| Market Cap | 10.98M |
| PE | -0.47 |
| EPS | -2.15 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 1.81 |
| Change | -0.12 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of March 03, 2026 at a share price of $1.02. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $3.21 as of March 03, 2026 at a share price of $1.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
Newsfile
Feb 19, 2026 12:00 PM GMT
Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Newsfile
Feb 10, 2026 12:00 PM GMT
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Newsfile
Jan 26, 2026 1:15 PM GMT
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing th